BioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 Disease
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the New England Journal of Medicine (NEJM) published updated results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
